Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 4
2012 1
2018 2
2019 1
2020 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
Hernández-Cruz B, Otero-Varela L, Freire-González M, Busquets-Pérez N, García González AJ, Moreno-Ramos M, Blanco-Madrigal JM, Manrique-Arija S, Perez-Pampin E, Ruiz-Montesino D, Sánchez-Alonso F, Sanchez-Piedra C, Castrejón I; BIOBADASER Study Group. Hernández-Cruz B, et al. Ann Rheum Dis. 2024 Aug 27;83(9):1189-1199. doi: 10.1136/ard-2023-225271. Ann Rheum Dis. 2024. PMID: 38594056 Free PMC article.
Cancer in patients with rheumatic diseases exposed to TNF antagonists.
Carmona L, Abasolo L, Descalzo MA, Pérez-Zafrilla B, Sellas A, de Abajo F, Gomez-Reino JJ; BIOBADASER Study Group; EMECAR Study Group. Carmona L, et al. Semin Arthritis Rheum. 2011 Aug;41(1):71-80. doi: 10.1016/j.semarthrit.2010.08.005. Epub 2010 Nov 18. Semin Arthritis Rheum. 2011. PMID: 21093020
Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER.
Bethencourt Baute JJ, Sanchez-Piedra C, Ruiz-Montesinos D, Medrano San Ildefonso M, Rodriguez-Lozano C, Perez-Pampin E, Ortiz A, Manrique S, Roselló R, Hernandez V, Campos C, Sellas A, Sifuentes-Giraldo WA, García-González J, Sanchez-Alonso F, Díaz-González F, Gómez-Reino JJ, Bustabad Reyes S; BIOBADASER study group. Bethencourt Baute JJ, et al. Arthritis Res Ther. 2018 Oct 10;20(1):227. doi: 10.1186/s13075-018-1728-3. Arthritis Res Ther. 2018. PMID: 30305158 Free PMC article.
Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry.
Hernandez MV, Sanchez-Piedra C, Garcia-Magallon B, Cuende E, Manero J, Campos-Fernandez C, Martin-Domenech R, Del Pino-Montes J, Manrique S, Castro-Villegas MC, Ruiz-Montesinos D, Sanchez-Alonso F, Diaz-Gonzalez F, Cea-Calvo L, Gómez-Reino JJ; BIOBADASER Study Group. Hernandez MV, et al. Rheumatol Int. 2019 Mar;39(3):509-515. doi: 10.1007/s00296-018-4177-z. Epub 2018 Oct 24. Rheumatol Int. 2019. PMID: 30353269 Free article.
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA, Gomez-Reino J, Alvaro-Gracia JM; BIOBADASER study group. Sanchez-Piedra C, et al. Ann Rheum Dis. 2020 Jul;79(7):988-990. doi: 10.1136/annrheumdis-2020-217948. Epub 2020 Jun 5. Ann Rheum Dis. 2020. PMID: 32503857 Free PMC article. No abstract available.